#Japan #Tokyo #Hepatitis C #Gracaprevir #Velpatasvir

AbbVie Seeks Expanded Treatment Options for Acute Hepatitis C in Japan

AbbVie, a global biopharmaceutical company headquartered in Tokyo's Minato Ward, has made a significant step by applying for additional approval of gracaprevir/velpatasvir as a treatment for acute hepatitis C in Japan. This submission aims to enhance treatment options for a disease that often progresses silently and can lead to chronic liver conditions, highlighting the urgent need for effective interventions.

Understanding Acute Hepatitis C

Acute hepatitis C is characterized by an infection caused by the hepatitis C virus (HCV), which spreads primarily through blood-to-blood contact. Often, patients remain asymptomatic, making diagnosis challenging. As indicated by Japan's liver disease guidelines, approximately 70% of those infected can develop chronic hepatitis C, which significantly increases the risk of severe liver issues like cirrhosis or even hepatocellular carcinoma over time.

Traditionally, the diagnosis of acute hepatitis C usually occurs through blood tests that reveal liver dysfunction. Many patients may not be aware of their infection until it progresses, underscoring the critical need for early antiviral treatment. The Japanese Society of Hepatology strongly promotes timely antiviral therapy for all hepatitis C patients to mitigate fibrotic progression and reduce the risk of liver cancer.

In Japan, treatment options for acute hepatitis C are currently limited, necessitating the need for more diverse therapeutic solutions. The approval of new treatments enhances the chances of initiating timely interventions, potentially decreasing both transmission rates and disease severity among affected individuals.

The Role of Gracaprevir/Velpatasvir

Gracaprevir/velpatasvir is a once-daily oral, ribavirin-free treatment option for patients aged three and older, approved for managing chronic hepatitis C virus infections. This direct-acting antiviral combines the NS3/4A protease inhibitor gracaprevir and the NS5A inhibitor velpatasvir, offering an effective approach to improve virologic response in adults and adolescents diagnosed with chronic hepatitis C or compensated cirrhosis.

Originally approved in September 2017, gracaprevir/velpatasvir represented Japan’s first eight-week treatment option specifically for treatment-naive adult patients infected with hepatitis C genotypes 1 and 2. Subsequent approvals expanded its use to include genotypes 3 to 6 and pediatric patients aged 12 years and older beginning in August 2019, and even younger children aged three years and older by June 2022.

Addressing Unmet Medical Needs

AbbVie's recent application for extended indication is grounded in the findings from a Phase 3 trial (M20-350), underscoring the significant unmet medical needs for patients battling acute hepatitis C. This initiative promises to drive progress in Japan's fight against hepatitis and aims to facilitate quicker treatment commencement following the confirmation of hepatitis C infection.

The move is indicative of AbbVie’s commitment to support liver disease eradication efforts and to broaden therapeutic avenues that enable early treatment and ultimately prevent further spread of the virus. The company actively collaborates with other stakeholders, including local health officials and medical communities, to promote awareness and education about hepatitis risks, the significance of HCV testing, and the need for prompt treatment.

AbbVie's Mission and Future Endeavors

AbbVie’s mission revolves around addressing today's healthcare challenges through innovative drug development and solutions tailored to tackle complex medical issues. The company focuses on enhancing the quality of life for individuals across various therapeutic areas, including immune disorders, oncology, neurology, and aesthetics. Their commitment extends to supporting the WHO's goal of hepatitis eradication, reflecting a broader strategy to improve treatment accessibility and outcomes for hepatitis patients across Japan.

In conclusion, AbbVie's application for gracaprevir/velpatasvir as a treatment for acute hepatitis C signifies a pivotal advancement in the Japanese healthcare landscape, aiming to address significant unmet needs while fostering collaboration for a healthier future.

For more information, visit AbbVie Japan.

References

1. Japanese Society of Hepatology C, Treatment Guidelines for Hepatitis C (8.4 Edition) 2025 April.
2. Hepatitis C. World Health Organization. Available at: WHO - Hepatitis C.